Cantor Fitzgerald analyst Charles Duncan raised his price target for Biohaven Pharmaceutical to $92 from $87 after hosting management in Europe for a week of investor meetings. The analyst has "enhanced conviction" about the company's potential value creation and reiterates an Overweight rating on the shares. Biohaven has a "better-than-even possibility" of being well prepared to launch rimegepant by establishing a commercially viable field force, possibly by the end of Q1 of 2020, and to having a "best-in-class" migraine drug, Duncan tells investors in a research note.

Biohaven is down -5.8%, or -$3.08 to $50.00.